Results 91 to 100 of about 22,540 (195)
Early tocilizumab and outcomes in acute necrotizing encephalopathy
Developmental Medicine &Child Neurology, EarlyView.Early tocilizumab and outcome in acute necrotising encephalopathy. Aim To evaluate the timing and safety of tocilizumab in acute necrotizing encephalopathy (ANE). Method This was a multicentre retrospective study evaluating outcomes (modified Rankin Scale [mRS]) in children with ANE treated with tocilizumab. A logistic regression model determined a cut‐
Velda X Han +14 more
wiley +1 more source
Therapeutic Advances in HematologyBackground: Hemophagocytic lymphohistiocytosis (HLH) is a rare life-threatening, hyperinflammatory syndrome for which etoposide-based regimens have historically been the standard of care.
Benjamin J. Lee
doaj +1 more source
European Journal of Haematology, EarlyView.ABSTRACT Objectives Baseline systemic inflammation has emerged as a determinant of outcome after CD19‐directed CAR‐T therapy. We evaluated the prognostic performance of the recently developed INFLAmmation MIXture Model (InflaMix) in an independent bicentric cohort of patients with large B‐cell lymphoma (LBCL) receiving commercial CAR‐T cells, focusing ...
Eugenio Galli +10 more
wiley +1 more source
Internal Medicine Journal, EarlyView.Abstract Chimeric antigen receptor (CAR) T‐cell therapies directed against cluster of differentiation 19 (CD19) are a standard of care for relapsed or refractory B‐cell lymphomas. Infection is the leading cause of non‐relapse mortality, and this risk may persist for years after CAR T‐cell receipt.
Aine Hurley +15 more
wiley +1 more source
Emerging Roles of PSTPIP2 in Autoimmunity: From Mechanism to Therapeutic Implications
Immunology, EarlyView.PSTPIP2 acts as a key brake on myeloid inflammation by suppressing IL‐1β‐driven signalling, macrophage dysregulation and inflammation‐associated bone remodelling. Its emerging roles in CRMO/CMO, rheumatoid arthritis, SAPHO syndrome and bullous pemphigoid support its potential as a biomarker and therapeutic target.
Erdong Zhang +9 more
wiley +1 more source
Innovations in Obesity Treatment: Beyond Adipose Tissue Dysfunction
Obesity Reviews, EarlyView.Obesity drives chronic inflammation, insulin resistance, type 2 diabetes, and cancer development through adipocyte dysfunction. Addressing this multisystemic disorder requires integrated strategies beyond diet and exercise, such as thermogenesis activation via menthol or capsinoids and appetite control through GLP‐1/GIP agonists and neuromodulation to ...
Jesica Martínez‐Godfrey +7 more
wiley +1 more source
Arthritis Care &Research, Volume 78, Issue 10, Page 1510-1521, October 2026.People with systemic autoimmune and rheumatic diseases (SARDs) are at higher risk than the general population of experiencing adverse pregnancy and perinatal outcomes such as preeclampsia, intrauterine growth restriction, and maternal and/or fetal death.
Mehret Birru Talabi, Sonya Borrero
wiley +1 more source
Wellcome Open ResearchBackground Novel host-directed therapies are urgently needed for patients with dengue, particularly those at high risk of developing severe disease.
Angela McBride +19 more
doaj +1 more source
Evaluating the Efficacy of Cytokine‐Directed Therapies in the Management of VEXAS Syndrome
ACR Open Rheumatology, Volume 8, Issue 10, October 2026.Objective To evaluate the efficacy of cytokine‐directed therapies in VEXAS (vacuoles, E1 enzyme, X‐linked, autoinflammatory somatic) syndrome using previously proposed treatment response criteria. Methods All patients with genetically confirmed VEXAS syndrome who received targeted therapies with JAK inhibitors (JAKi), tumor necrosis factor α inhibitors
Daniel Montes +15 more
wiley +1 more source